Claims for Patent: 8,680,256

Summary for Patent: 8,680,256

Title:	Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses
Abstract:	The present invention relates to a (first) method for producing inducible and/or repressible expression active linear RNA interference constructs comprising a PCR amplification of a source polynucleotide comprising the inhibitory RNA coding sequence of interest or comprising a PCR amplification of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest. The present invention furthermore relates to a (second) method for producing inducible and/or repressible expression active linear gene constructs comprising a PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or comprising a PCR amplification using the DNA sequence as a template. The present invention furthermore relates to libraries, arrays, cells and cell lines and kits utilizing the inducible and/or repressible expression active linear RNA interference constructs or the inducible and/or repressible expression active linear gene constructs.
Inventor(s):	Abu Khabar; Khalid S. (Riyadh, SA)
Assignee:	King Faisal Specialist Hospital & Research Centre (Riyadh, SA)
Application Number:	13/001,303
Patent Claims:	1. A method for producing inducible expression active linear gene constructs, comprising the step of: (a) generating an inducible expression active linear gene construct, comprising one or more control element(s) that are inducible element(s), a minimal promoter comprising a transcriptionally non-inducible constitutively active ribosomal protein gene promoter, a DNA sequence selected from a gene, a coding region, an open reading frame (ORF), an inhibitory RNA coding sequence and a cDNA, a 3' untranslated region (3' UTR) containing mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA, and a termination sequence, wherein the generating step comprises a PCR amplification of a source expression polynucleotide comprising in 5' to 3' direction a promoter sequence and the DNA sequence using (i) a forward primer comprising at its 3' end, a first sequence part complementary to a promoter region of the source expression polynucleotide upstream of the DNA sequence, and at its 5' end a second sequence part comprising one or more introduced control element(s); and (ii) a reverse primer selected from a reverse primer complementary to a region of the source expression polynucleotide downstream of the DNA sequence, wherein the primer comprises mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA and a termination sequence, or a reverse primer complementary to a region of the source expression polynucleotide downstream of a 3' UTR wherein the region contains mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA, wherein the source expression polynucleotide is a vector, a lentivirus, a plasmid, a virus-based vector, or a linear or linearized or amplified fragment thereof, wherein the mRNA destabilization elements are selected from AU-rich elements, GU-rich elements, and U-rich sequences, wherein the mRNA stabilization elements are selected from GC-rich elements, CU-rich elements, and UG-rich sequences, wherein the generating step does not involve a cloning step, wherein said cloning step includes the use of one or more of restriction digestion, cloning enzyme(s), bacterial transformation and plasmid preparation, and wherein expression of the inducible expression active linear gene construct resulting from (a) can be induced by the addition of a compound that activates the expression or by the withdrawal of a compound that represses the expression. 2. The method of claim 1, further comprising the following steps: (b) transfecting a cell or cell line with the inducible expression active linear gene construct obtained in step (a) of claim 1; wherein the cell or cell line transiently or stably expresses a repressor system, (c) expressing a protein encoded by the DNA sequence contained in the inducible expression active linear gene construct obtained in step (a) of claim 1 by the addition of a compound that activates the expression or by the withdrawal of a compound that represses the expression; and (d) measuring gene expression level or activity of the protein expressed in step (c). 3. The method according to claim 1, wherein the minimal promoter is a RPS23 promoter or a RPS30 promoter, which is modified for higher expression by modifying the transcriptional initiation sequence. 4. The method according to claim 3, wherein the minimal promoter further comprises at least one sp1 site-containing sequence. 5. The method according to claim 3, wherein the minimal promoter further comprises intron sequence(s) of ribosomal proteins, exon sequence(s) of ribosomal proteins, and/or modified sequences wherein the modification eliminates a restriction site. 6. The method according to claim 3, wherein the minimal promoter comprises a nucleic acid sequence of any of SEQ ID NOs. 3 to 8. 7. The method according to claim 1, wherein the termination sequence comprises an eukaroytic polyadenylation signal, pol III termination signal, thymidines stretch, U1 termination signal, pol I termination signal, or a synthetic termination variant. 8. The method according to claim 1, wherein the inducible control element is selected from the group consisting of a tetracycline (TetO) system, an ecdysone inducible system, a heat shock on system, a lacO/IPTG system, a cre system, a cumate repressor protein CymR system, a nitroreductase system, a coumermycin/novobiocin-regulated system, a RheoSwitch Ligand RSL 1 system, a chimeric bipartite nuclear receptor expression system, a GAL4 system. 9. The method according to claim 1, wherein the inducible control elements are CpG island containing sequences. 10. The method according to claim 1, wherein the forward primer comprises one or more regulatory sequence element(s) or transcriptional element(s) selected from transcriptional enhancing and translational enhancing element(s). 11. The method according to claim 1, wherein the forward primer comprises a nucleic acid sequence selected from SEQ ID NOs. 13 or 14. 12. The method according to claim 1, wherein the DNA sequence encodes a gene which is selected from the group consisting of: reporters, fluorescent reporters, green fluorescent protein (GFP) and derivatives, enhanced green fluorescent protein (EGFP) and derivatives, luciferase, modified luciferase, inhibitory RNA coding sequences, secreted reporter forms, alkaline phosphatase, CAT, .beta.-galactosidase, antibodies, immunoglobin fragments, cDNA fragments, open reading frames (ORF), and domain sequences. 13. The method according to claim 1, wherein the inhibitory RNA coding sequence is selected from a coding DNA sequence for short hairpin RNA (shRNA), small interfering RNA (siRNA), micro RNA (miRNA) and antisense RNA. 14. A method for producing repressible expression active linear gene constructs, comprising the step of: (a) generating a repressible expression active linear gene construct, comprising one or more control element(s) that are inducible element(s), a minimal promoter comprising a transcriptionally non-inducible constitutively active ribosomal protein gene promoter, a DNA sequence selected from a gene, a coding region, an open reading frame (ORF) an inhibitory RNA coding sequence and a cDNA, a 3' untranslated region (3' UTR) containing mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA, and a termination sequence, wherein the generating step comprises a PCR amplification of a source expression polynucleotide comprising in 5' to 3' direction a promoter sequence and the DNA sequence using (i) a forward primer comprising at its 3' end, a first sequence part complementary to a promoter region of the source expression polynucleotide upstream of the DNA sequence, and at its 5' end a second sequence part comprising one or more introduced control element(s); and (ii) a reverse primer selected from a reverse primer complementary to a region of the source expression polynucleotide downstream of the DNA sequence, and wherein the primer comprises mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA and a termination sequence, or a reverse primer complementary to a region of the source expression polynucleotide downstream of 3' UTR wherein the region contains mRNA destabilization or stabilization elements of a 3' UTR of a cellular mRNA, wherein the source expression polynucleotide is a vector, a lentivirus, a plasmid, a virus-based vector, or a linear or linearized or amplified fragment thereof, wherein the mRNA destabilization elements are selected from AU-rich elements, GU-rich elements, and U-rich sequences, wherein the mRNA stabilization elements are selected from GC-rich elements, CU-rich elements, and UG-rich sequences, wherein the generating step does not involve a cloning step, wherein said cloning step includes the use of any one or more of restriction digestion, cloning enzyme(s), bacterial transformation and plasmid preparation, and wherein expression of the inducible expression active linear gene construct resulting from (a) can be induced by the addition of a compound that activates the expression or by the withdrawal of a compound that represses the expression. 15. The method of claim 14, further comprising the following steps: (b) transfecting a cell or cell line with the repressible expression active linear gene construct obtained in step (a) of claim 14; wherein the cell or cell line transiently or stably expresses a repressor system, (c) expressing a protein encoded by the DNA sequence contained in the repressible expression active linear gene construct obtained in step (a) of claim 14 by the addition of a compound that represses the expression or by the withdrawal of a compound that activates the expression; and (d) measuring gene expression level or activity of the protein expressed in step (c). 16. The method according to claim 14, wherein the minimal promoter is RPS23 promoter or RPS30 promoter, which is modified for higher expression by modifying the transcriptional initiation sequence. 17. The method according to claim 14, wherein the termination sequence comprises an eukaroytic polyadenylation signal, pol III termination signal, thymidines stretch, U1 termination signal, pol I termination signal, or a synthetic termination variant. 18. The method according to claim 14, wherein the repressible expression element is selected from the group consisting of a tetracycline (TetO) system, a heat shock off system, a lacO/IPTG system, a cre system, a nitroreductase system, a coumermycin/novobiocin-regulated system, a RheoSwitch Ligand RSL1 system, a chimeric bipartite nuclear receptor expression system, a GAL4 system. 19. The method according to claim 14, wherein the forward primer comprises one or more regulatory sequence element(s) or transcriptional element(s) selected from transcriptional enhancing and translational enhancing element(s). 20. The method according to claim 14, wherein the forward primer comprises a nucleic acid sequence selected from of SEQ ID NOs. 13 or 14. 21. The method according to claim 14, wherein the DNA sequence encodes a gene which is selected from the group consisting of: reporters, fluorescent reporters, green fluorescent protein (GFP) and derivatives, enhanced green fluorescent protein (EGFP) and derivatives, luciferase, modified luciferase, inhibitory RNA coding sequences, secreted reporter forms, alkaline phosphatase, CAT, .beta.-galactosidase, antibodies, immunoglobin fragments, cDNA fragments, open reading frames (ORF), and domain sequences.

Details for Patent 8,680,256

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-06-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-06-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-06-27